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“Swallowing the doctor”: an interview with João
Conde about the future of nanomedicine
João Conde began his independent career at NOVA Medical School of Universidade Nova de Lisboa in the beginning of 2020. In
this short Q&A he tells us about his experience as an early career researcher, challenges he faced with science under lockdown,
the advice he has for his younger self and what is the most likely science fiction vision we can achieve with nanotechnology.
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Can you tell us about your research interests?
The main focus of our research group is the use of cancer
nanotechnology for precision medicine in order to tackle real
and crucial medical problems involved in the development of
novel and highly effective diagnostic and therapeutic platforms
for cancer. Cancer has become the chief in providing
groundbreaking platforms that can be used for precision
medicine. Determining the response profile of a tumor,
detecting key driver players in tumor progression, and trying to
disable those drivers with targeted therapies and engineered
materials so as to “smash” the brakes on malignant and
metastatic cells to control proliferation is the modus operandi
of our group.
Cancer nanotechnology is becoming a burgeoning field and
our research brings up reality to the precision medicine initia-
tive. Our research empowers the potential of nanomedicine to
differentially combat cancer using smart and targeted platforms
that mediate highly selective therapies within the tumor
microenvironment. It is imperative to learn how advances in
nanosystem capabilities are being used to identify new ther-
apeutic tools driving the development of personalized medi-
cine in different cancer types and disease states and recognize
how to translate nanotechnology data and patients-derived
Intel into an effective clinical strategy. The lack of standar-
dized means to treat and profile the tumor microenvironment
calls for a paradigm shift in the way we view and treat cancer.
Is in this paradigm that our research focus: tackling real
biomedical problems and develop smart materials to beat
cancer.
Where did you find the initial spark for your interest in
nanomedicine?
My initial spark for nanomedicine started when I read a
transcript of the talk “Plenty of Room at the Bottom” by Richard
P. Feynman in 1959 to the American Physical Society in Pasa-
dena, which explores the immense possibilities afforded by
miniaturization.
In this well-known talk, Feynman placed the theoretical
foundations for the field now called nanotechnology when he
conceived of a world in which things could be miniaturized, or
huge volumes of information could be programmed onto smaller
and smaller devices, and when machines could be made sig-
nificantly reduced and compact. Despite the fact that 1959 was
the time when computers were the size of entire rooms, Feynman
asked his audience: “I don’t know how to do this on a small scale
in a practical way, but I do know that computing machines are
very large; they fill rooms. Why can’t we make them very small,
make them of little wires, little elements, and by little, I mean
little?”.
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In fact, the concept of miniature medical minions isn’t new.
Richard Feynman at that time already suggested the possibility of
“swallowing the doctor”. Feynman told us “it would be interesting
in surgery if you could swallow the surgeon (small machine). (…)
It goes into the heart and looks around. It finds out which valve is
the faulty one” and repairs it.
That truly inspired me to use nanomedicine as a powerful tool
to diagnose and treat diseases like cancer.
What are your predictions for your field in the near future,
given the underwhelming response of nanomedicines in clin-
ical trials?
It is forecast that nanomedicine will definitely help move for-
ward cancer treatments in patients, focusing on the combination
of stratagems that are able to assemble converging therapy
opportunities based on the “intel” from individual patients’
molecular signatures and innovative and efficient delivery vehicles.
Nevertheless, considering the extensive reports of anticancer
nanomedicines in preclinical studies, we need to face the fact that
there is a paucity of clinical trials using these therapies. We know
that nanotechnology can certainly deliver, but we need to tackle
the limitations that are holding back the translation of nanome-
dicines into the clinic and start benefiting from their full potential.
I believe that there is an earnest need to develop improved
delivery vehicles and to establish guidelines regarding the per-
formance metric by which we can evaluate a technology in a
preclinical setting. Correlating preclinical and clinical outcomes
would pave the way to generating a scoring system that would
determine the probability of clinical success.
For successful translation into the clinic, an improvement in
delivery efficiency must be realized through a mechanistic
understanding of: (i) the characteristics of the tumor milieu; (i)
the cancer response to a certain therapy; and (iii) the formation of
criteria with which to assess therapeutic success based on a
multifaceted metric that considers tumor size, survival rate, the
nanomaterials’ pharmacokinetic/pharmacodynamic properties;
and biodistribution, in order to enable correlations between
preclinical and clinical settings.
From defeating the inconsistency in preclinical studies to
enabling existing and broadly utilized systemic therapies with
groundbreaking and proficient local platforms, one can influence
existing and future studies to impart improved technologies with
prognostic therapeutic performance. I believe the implementation
of these guidelines can potentiate the development of a new
generation of standardized drug delivery nanosystems.
Can you tell us about the challenges you had to face as a PI
of a young lab due to the shutdown caused by the current
pandemic? Has it affected the postdoctoral and graduate stu-
dent funding and thus career development?
I remember perfectly well the day when the WHO Director-
General declared the novel coronavirus outbreak a pandemic and
a public health emergency of international concern. On this same
day, the world changed unimaginably. I believe this is a historical
moment as this new coronavirus changed life, every day, for all of
us around the world.
And it was no different for our lab. Especially for a newly
formed group, it was hard to stop all lab work and stay at home.
Although this was necessary, it’s a fact that affected all of us and
affected career development as we were unable to work in the lab
for several months. However, this pandemic also brought us more
time to think of future projects and new ideas to develop, and to
write more opinion and review pieces.
Above all, this pandemic brought to all the understanding that
science and medicine are more important than ever.
What advice would you give to your younger self?
The main advice I would give to my younger self is to be happy
with what you do but at the same time to relativize things always.
I believe this is the key to everything.
I always have this quote in mind from Marcel Pagnol, who was
a French novelist, playwright, and filmmaker: “The reason people
find it so hard to be happy is that they always see the past better
than it was, the present worse than it is, and the future less
resolved than it will be”.
Which is the most probable “science-fiction” scenario that
you think could become reality, specifically with respect to
cancer therapy?
I believe that idea from Richard Feynman represents that per-
fect “science-fiction” scenario that could become reality in cancer
therapy: “swallowing the doctor” and having tiny machines that
localize the error in cells and fix it. Achieving “the next big thing”
starts with having these smart machines that could deliver drugs
effectively to the most complex cell network – the tumor. In fact,
the tumor microenvironment is a rough neighborhood for
nanomaterials. Tumors create skewed neighborhoods, embedded
with their leaky and chaotic blood vessels that are like broken
roads or damaged sewers. All the different cells composing the
tumor milieu actually shift to support tumor growth, these
unoccupied lots densely overgrown with collagen fibers. And we
are trying the get a huge truckload of medicines into all of this. Is
not an easy task but I believe we are getting closer to building
these tiny machines and to realizing Feynman’s “prophecy”.
The editors at Communications Biology invite submissions in all
areas of nanomedicine. For more details see our recent editorial on
the subject.
This interview was conducted by Associate Editor Anam Akhtar.
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